Imatinib as an Adjuvant in Localized Gastrointestinal Stromal Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Final Analysis of the Randomized Trial on Imatinib as an Adjuvant in Localized Gastrointestinal Stromal Tumors (GIST) From the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS)
Ann. Oncol 2021 Jan 19;[EPub Ahead of Print], PG Casali, A Le Cesne, AP Velasco, D Kotasek, P Rutkowski, P Hohenberger, E Fumagalli, IR Judson, A Italiano, H Gelderblom, N Penel, HG Kopp, F Duffaud, D Goldstein, JM Broto, A Gronchi, E Wardelmann, S Marréaud, JR Zalcberg, S Litière, JY BlayFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.